Literature DB >> 17851959

Activities of matrix metalloproteinases and tissue inhibitor of metalloproteinase-2 in idiopathic hemotympanum and otitis media with effusion.

Sung K Moon1, Fred H Linthicum, Hae Dong Yang, Seung Joo Lee, Keehyun Park.   

Abstract

CONCLUSION: The expression profile of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase-2 (TIMP-2) was specific to the type of middle ear effusion. Further studies are necessary for elucidating its correlation with the sequelae of otitis media with effusion (OME) and idiopathic hemotympanum.
OBJECTIVES: We aimed to investigate the relative activities of gelatinases (MMP-2 and -9), stromelysin-1 (MMP-3), and matrilysin-1 (MMP-7), as well as measuring TIMP-2 levels in the serous and mucous effusions of OME and hemorrhagic effusion of the idiopathic hemotympanum.
MATERIALS AND METHODS: Middle ear effusions were collected from patients with OME and idiopathic hemotympanum, and were classified as mucoid, serous, or hemorrhagic. MMP activity in the effusion samples was examined by gelatin and casein zymography. Levels of TIMP-2 were measured by ELISA. Human temporal bone sections, with and without otitis media (OM), were examined histologically.
RESULTS: One case showed tympanic membrane thinning in the OM group, but none in the control group. While MMP-2 was present in all effusions, the active form of MMP-2 was found only in mucous effusions. MMP-3 and MMP-7 activity was detected only in the mucous effusions. MMP-9 exhibited activity in all effusions, with the highest levels in mucous effusions. TIMP-2 levels were markedly elevated in serous effusions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17851959      PMCID: PMC2577605          DOI: 10.1080/00016480701477610

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  20 in total

Review 1.  Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention.

Authors:  W G Stetler-Stevenson
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

2.  Eustachian tube function and tympanic membrane findings after chronic secretory otitis media.

Authors:  Marie Ryding; Peter White; Olof Kalm
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2004-02       Impact factor: 1.675

Review 3.  Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors.

Authors:  Patricia A M Snoek-van Beurden; Johannes W Von den Hoff
Journal:  Biotechniques       Date:  2005-01       Impact factor: 1.993

4.  Matrix metalloproteinases 2 and 9 in otitis media with effusion.

Authors:  C R Jennings; L Guo; H M Collins; J P Birchall
Journal:  Clin Otolaryngol Allied Sci       Date:  2001-12

5.  Long-term effects of otitis media with effusion: otomicroscopic findings.

Authors:  A G Schilder; G A Zielhuis; M P Haggard; P van den Broek
Journal:  Am J Otol       Date:  1995-05

Review 6.  Tissue inhibitors of metalloproteinases: structure, regulation and biological functions.

Authors:  D E Gomez; D F Alonso; H Yoshiji; U P Thorgeirsson
Journal:  Eur J Cell Biol       Date:  1997-10       Impact factor: 4.492

7.  Alpha 1-antitrypsin and ilomastat inhibit inflammatory proteases present in human middle ear effusions.

Authors:  Patrick J Antonelli; Gregory S Schultz; Karen M Kim; John S Cantwell; David J Sundin; Philip A Pemberton; Philip J Barr
Journal:  Laryngoscope       Date:  2003-08       Impact factor: 3.325

8.  Matrix metalloproteinase-2 and matrix metalloproteinase-9 in cholesteatoma and deep meatal skin.

Authors:  A R Banerjee; R James; A A Narula
Journal:  Clin Otolaryngol Allied Sci       Date:  1998-08

9.  Expression of matrix-metalloproteinases and their inhibitors in human cholesteatomas.

Authors:  M Schönermark; B Mester; H G Kempf; J Bläser; H Tschesche; T Lenarz
Journal:  Acta Otolaryngol       Date:  1996-05       Impact factor: 1.494

10.  Matrix metalloproteinases in a gerbil cholesteatoma model.

Authors:  Jason G Wilmoth; Gregory S Schultz; Patrick J Antonelli
Journal:  Otolaryngol Head Neck Surg       Date:  2003-10       Impact factor: 5.591

View more
  7 in total

1.  Tissue remodeling in the acute otitis media mouse model.

Authors:  Nathan B Sautter; Katherine L Delaney; Frances A Hausman; Dennis R Trune
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2011-09-01       Impact factor: 1.675

Review 2.  Molecular mechanisms of moraxella catarrhalis-induced otitis media.

Authors:  Ferdaus Hassan
Journal:  Curr Allergy Asthma Rep       Date:  2013-10       Impact factor: 4.806

3.  Inner ear tissue remodeling and ion homeostasis gene alteration in murine chronic otitis media.

Authors:  Carol J MacArthur; Fran Hausman; J Beth Kempton; Nathan Sautter; Dennis R Trune
Journal:  Otol Neurotol       Date:  2013-02       Impact factor: 2.311

4.  Role of c-Jun N-terminal protein kinase 1/2 (JNK1/2) in macrophage-mediated MMP-9 production in response to Moraxella catarrhalis lipooligosaccharide (LOS).

Authors:  Ferdaus Hassan; Dabin Ren; Wenhong Zhang; Xin-Xing Gu
Journal:  PLoS One       Date:  2012-05-24       Impact factor: 3.240

5.  Preventive effect of halofuginone on concanavalin A-induced liver fibrosis.

Authors:  Jie Liang; Bei Zhang; Ruo-wu Shen; Jia-Bao Liu; Mei-hua Gao; Ying Li; Yuan-Yuan Li; Wen Zhang
Journal:  PLoS One       Date:  2013-12-16       Impact factor: 3.240

6.  The possible mechanism of Hippophae fructus oil applied in tympanic membrane repair identified based on network pharmacology and molecular docking.

Authors:  Juntao Huang; Bing Mei Teh; Ziqian Xu; Zhechen Yuan; Chongchang Zhou; Yunbin Shi; Yi Shen
Journal:  J Clin Lab Anal       Date:  2021-12-03       Impact factor: 2.352

7.  Otitis media in the Tgif knockout mouse implicates TGFβ signalling in chronic middle ear inflammatory disease.

Authors:  Hilda Tateossian; Susan Morse; Andrew Parker; Philomena Mburu; Nick Warr; Abraham Acevedo-Arozena; Michael Cheeseman; Sara Wells; Steve D M Brown
Journal:  Hum Mol Genet       Date:  2013-03-03       Impact factor: 6.150

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.